Competition/Antitrust

Axinn has more than 70 full time antitrust lawyers working on M&A, litigation, criminal and conduct investigations. The firm has been a global lead on mergers worth close to half a trillion dollars, including: Dell’s US$67 billion acquisition of EMC; Thermo Fisher’s US$13.6 billion acquisition of Life Technologies and US$12.5 billion tender offer of Qiagen; Tyson Foods’ US$2.16 billion acquisition of Keystone Foods and US$1.2 billion sale of its pet treats business; Ball Corporation’s US$6 billion acquisition of Rexam; Johnson Controls’ US$2 billion sale of Scott Safety to 3M; McKesson’s US$3.4 billion joint venture with Change Healthcare; and Google’s most complex deals, including Motorola Mobility and ITA Software. Axinn has extensive experience in major trials and class actions, including the ad technology business litigations (for Google), the multiple major treble-damage class action litigations and regulatory investigations (for Tyson Foods); a patent infringement and antitrust litigation regarding Indivior’s opioid dependency treatment drug Suboxone® Film and the Generic Drugs MDL (for Alvogen); the In Re Surescripts monopolisation class action (for RelayHealth (McKesson)); and In Re Blue Cross antitrust litigation (for Independence Health Group). The firm has litigated six merger cases brought by government agencies (winning five). Axinn has deep contacts with the staff and front offices of the FTC and the DOJ in both Republican and Democratic administrations.